PRVA - Privia Health Group, Inc.
Investors interested in Medical Info Systems stocks are likely familiar with TruBridge (TBRG) and Privia Health (PRVA). But which of these two stocks presents investors with the better value opportunity right now?
Privia Health Group NASDAQ: PRVA reported a strong first quarter, with executives pointing to double-digit provider growth, a larger value-based care population and margin expansion as signs that the company's operating model continues to scale.
Privia Health Group, Inc. (PRVA) Q1 2026 Earnings Call Transcript
Although the revenue and EPS for Privia Health (PRVA) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Privia Health (PRVA) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.03 per share a year ago.
Privia Health Reports First Quarter 2026 Financial Results; Strong First Quarter Performance and Operating Execution; Reiterated Full-Year 2026 Guidance
ARLINGTON, Va., April 08, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that it expects to release financial results for its first quarter ended March 31, 2026 before market open on Thursday, May 7, 2026.
JPMorgan Chase and Co. increased its holdings in Privia Health Group, Inc. (NASDAQ: PRVA) by 26.2% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 148,709 shares of the company's stock after acquiring an additional 30,845 shares during
ARLINGTON, Va., March 24, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) announced that its network of affiliated medical groups, collectively Privia Medical Group, has been named a recipient of the 2026 MAP (Measure, Apply, Perform) Award for High Performance in Revenue Cycle, sponsored by the Healthcare Financial Management Association (HFMA).
Privia Health's CFO sold 13,018 direct shares for approximately $283,000 over two days, at an average price of $21.71 per share. The sale represented 5.24% of the CFO's total direct holdings as of the transaction dates.
The average of price targets set by Wall Street analysts indicates a potential upside of 43.4% in Privia Health (PRVA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Shares of Privia Health Group, Inc. (NASDAQ: PRVA - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the sixteen ratings firms that are presently covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The
WILMINGTON, Del.--(BUSINESS WIRE)-- #AIinHealthcare--Amalgam Rx, Inc., a leader in data-driven, AI-powered healthcare engagement and clinical decision support, today announced results from a Privia Health (NASDAQ: PRVA)-led colorectal cancer (CRC) screening program, supported by Amalgam Rx, Inc. and Exact Sciences Corp. (NASDAQ: EXAS). Documented in a published Privia Health case study, the program demonstrates how EHR-integrated workflows and proactive patient outreach supported an increase of CRC screening rat.
The mean of analysts' price targets for Privia Health (PRVA) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Privia Health Group, Inc. (PRVA) Q4 2025 Earnings Call Transcript
Although the revenue and EPS for Privia Health (PRVA) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Privia Health (PRVA) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.03 per share a year ago.
All 2025 Operating and Financial Metrics At or Above High End of Guidance Ranges Full-year 2025 Net Income +59.3% from 2024 Full-year 2025 Adjusted EBITDA of $125.5 Million, +38.8% from 2024 Full-year 2025 Net Cash Provided by Operating Activities of $163.4 Million , +49.5% from 2024; Year-end 2025 Cash Balance of $479.7 Million and No Debt 2026 Guidance Reflects ~20% Adjusted EBITDA Growth at Midpoint ARLINGTON, Va., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced financial and operating results for the fourth quarter and full year ended December 31, 2025.
Evaluate the expected performance of Privia Health (PRVA) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Privia Health Group (NASDAQ: PRVA - Get Free Report) is anticipated to issue its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of $0.04 per share and revenue of $516.6090 million for the quarter. Individuals can find conference call details on the company's upcoming Q4 2025